News | October 25, 2010

Dutch Court Rules in Favor of Occlutech in AGA Patent Case

October 25, 2010 – The Hague, Netherlands ruled in favor of Occlutech, a transcatheter structural heart occluder device maker, in the ongoing patent litigation with AGA Medical. The lawsuit stems from AGA alleging Occlutech’s technology infringes on its Amplatzer transcatheter occluder device patents.

AGA had appealed the court ruling in Occlutech’s favor in 2008. In the new ruling, the appeal court of The Hague saw no reason to change the favorable first instance ruling. The Dutch appeal court decision is similar to the appeals court rulings in the United Kingdom, which were received in mid-2010. The rulings are subject to further appeal by AGA.

Occlutech lost in the German district and appeal courts of Dusseldorf in 2007 and 2008, causing a halt of sales and manufacturing activities in Germany. But the German Supreme Court, (BGH), recently announced that it has allowed Occlutech's appeal. Occlutech expects a final decision in the first half of 2011.

If that case is decided in Occlutech's favor, the company said it plans to seek substantial claims for repayments and damages. Due to the litigation activity, Occlutech has lost revenue, had products destroyed and suffered the cost of litigation leading to potential damage claims in excess EUR 50 million.

AGA was recently purchased by St. Jude Medical.

For more information: www.occlutech.com

Related Content

Videos | Structural Heart Occluders | November 08, 2017
John Rhodes, M.D., co-director of the adult congenital heart program, Medical University of South Carolina, is the pr
Videos | Structural Heart Occluders | September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
University of Alabama at Birmingham, Amplatzer PFO Occluder, first implementation
News | Structural Heart Occluders | February 15, 2017
Doctors at the University of Alabama at Birmingham have implemented the first U.S. Food and Drug Administration (FDA)-...
Amplatzer PFO Occluder, St. Jude Medical, Baylor Heart and Vascular Services, Fort Worth, Texas, first patients
News | Structural Heart Occluders | February 01, 2017
Baylor Heart and Vascular Services at Fort Worth in November became the first program in Texas to implant the Amplatzer...
RESPECT trial, Amplatzer PFO Occluder, St. Jude Medical, TCT 2016
News | Structural Heart Occluders | November 02, 2016
St. Jude Medical Inc. announced the long-term data from RESPECT, a landmark trial, during a First Report session at the...
St. Jude Medical, Amplatzer PFO Occluder, FDA approval, U.S. launch
Technology | Structural Heart Occluders | November 02, 2016
St. Jude Medical Inc. announced this week the U.S. Food and Drug Administration (FDA) approval and launch of the...
PFO closure, patent foramen ovale, AAN recommendation, American Academy of Neurology, stroke patients
News | Structural Heart Occluders | August 08, 2016
Updated recommendations from the American Academy of Neurology (AAN) states that catheter-based closure should not be...
Videos | Structural Heart Occluders | June 16, 2016
This is an animation, supplied by Gore, demonstrated how the Cardioform Septal Occluder is implanted for the transcat
PFO occluder, amplatzer
Feature | Structural Heart Occluders | May 27, 2016 | Dave Fornell
May 27, 2016 — A U.S.
Videos | Structural Heart Occluders | November 05, 2012
Positive results from the RESPECT trial of transcatheter PFO vs.
Overlay Init